Effects of Totally Synthetic, Low Phenylalanine Diet on Adolescent Phenylketonuric Patients

CHARLES M. McKEAN

From Brain-Behavior Research Center, Sonoma State Hospital, Eldridge, California 95431, U.S.A.

McKeen, C. M. (1971). Archives of Disease in Childhood, 46, 608. Effects of totally synthetic, low phenylalanine diet on adolescent phenylketonuric patients. The long-term responses of 5 adolescent phenylketonuric patients to chemically-defined, synthetic diets with normal and low phenylalanine content were determined.

The synthetic preparations were found capable of sustaining good health and rapid growth in this group of profoundly retarded, behaviourally disturbed patients over a 3½-year period without clinical or biochemical evidence of nutritional inadequacy. 4 of these patients who were treated for 6 months on a comparable diet, in which 80% of the phenylalanine was replaced by tyrosine, continued to show weight maintenance and height increases. There was no evidence of poor acceptability of the imbalanced diet, whether the blood phenylalanine concentrations were at phenylketonuric or treatment levels. The phenylalanine intake required to maintain blood phenylalanine concentrations of 3-5 mg/100 ml in these 4 patients was well below normal requirements, and ranged between 6.8 and 20.1 mg/kg per day. Predictably, the phenylalanine requirement varied with individual growth rates.

All 4 treated patients had objective signs of improved central nervous system function during the six-month period on the phenylalanine-restricted diet. These electrophysiological and behavioural improvements were manifest after blood phenylalanine concentrations fell below 12 mg/100 ml in 3 cases and below 5 mg/100 ml in the fourth.

The enthusiasm that followed Bickel’s first report (Bickel, Gerrard, and Hickmans, 1953) on the successful dietary treatment of phenylketonuria in 1953 has been tempered recently by an increasing awareness of the hazards implicit in such nutritional manipulation. Concern has centred around three potential hazards. The most serious of these is the possibility that rigorous dietary regimens may be seriously deficient in phenylalanine for meeting the requirements of rapid physical growth which could, in fact, impair the cerebral development of patients whom the diets are designed to protect. That this may be a valid concern is suggested by the work of Fuller and Shuman (1969) in which both overtreatment and undertreatment were associated with deteriorating intellectual performance in phenylketonuric individuals. Furthermore, there has been speculation that totally synthetic diets provide inadequate amounts of certain unspecified nutrients found only in natural foodstuffs. Finally, it has been suspected that imbalanced amino acid composition may lead to poor acceptance of the dietary preparation of interfere with normal protein synthesis. Harper (1958) and others have observed a consistent depression of food intake and retarded growth in rats fed diets that are very deficient in a single amino acid. It has been suggested that ‘the changed blood amino acid pattern serves as a signal that activates an appetite-regulating mechanism, while the pattern is an indirect reflection of some more subtle change, possibly at sites of protein synthesis’ (Yoshida et al., 1966). Controlled observations have not been made to determine whether humans are similarly affected.

The present study will attempt to deal with the following questions.

Received 6 April 1971.
Effects of Synthetic, Low Phenylalanine Diet on Adolescent Phenylketonuric Patients 609

(1) Can a chemically-defined totally synthetic diet meet the complex nutritional demands and the overall health requirements of a rapidly growing phenylketonuric patient over a period of years?

(2) Is the same diet, when imbalanced with respect to phenylalanine, less acceptable than a balanced one?

(3) Is the imbalanced diet as efficient nutritionally in maintaining positive nitrogen balance, as reflected in stable body weight?

(4) Do the phenylalanine requirements of these phenylketonuric patients fall within the normal range?

(5) Is there evidence of improvement in central nervous system function on the low phenylalanine synthetic regimen in these profoundly retarded, adolescent patients?

Previous studies have compared the effects of normal, unrestricted diets of natural food with low phenylalanine regimens which are generally quasi-synthetic. Consequently, the effect of amino acid imbalance could not be distinguished from that of other nutritional differences. In the first phase of our investigations we have made an effort to compare the growth of 5 pubertal phenylketonuric patients on natural food with that on a chemically-defined, totally synthetic diet with normal phenylalanine composition. In the latter phase, we have examined the acceptability and nutritional efficiency of the same synthetic diet with 80% of its phenylalanine replaced by tyrosine.

Materials and Methods

Subjects. Five ambulatory phenylketonuric patients (4 males and 1 female) in the metabolic ward of the Research Center at Sonoma State Hospital. These children at the outset of the study ranged from 7 to 11 years of age and from 9 to 14 years when the synthetic diet was initiated. They were essentially mute, with unobtainable IQ scores on the Wechsler or Stanford-Binet batteries, but capable of following simple instructions. All represented problems in behavioural management.

Dietary Regimens

(1) Normal hospital diet. This consisted of the usual mixed institutional fare which is closely controlled nutritionally by hospital dietitians. This diet provided approximately 70–80 Cal/kg and 1·6 g protein/kg for children ranging initially between 6–10 years of age.

(2) Chemically-defined, synthetic diets

(A) Diet with normal phenylalanine content. The diets employed in this portion of the studies were generously donated by Vivonex Corporation, Mountain View, California. This synthetic preparation* was based on a chemically-defined liquid diet, originally designed for animal experimentation (Greenstein et al., 1957) and later adapted for human use (Winitz et al., 1965). It was provided as a powder which was mixed with water. The resulting orange-flavoured liquid proved acceptable as the sole source of nutrition after a period of acclimatization of 1–4 weeks. Table I indicates its composition.

*Vivonex-100.
the weight was healing Wound in a 10 kg (Case 1)

(2) Electrophysiological. Standard electroencephalo-
grams were obtained under postprandial conditions just
before shifting to the low phenylalanine diet; then, 3
and 6 months after the diet was begun.

Results and Discussion

Physical examination. At no time was there
a noteworthy change in status by physical examina-
tion except for the signs accompanying an exotic
attack of appendicitis which followed the ingestion
of a metal screw which subsequently lodged in the
appendix of the only female patient in the study
(Case 5). The stormy and baffling course resulted
in a 10 kg weight loss before surgical intervention.
Wound healing was rapid on the synthetic diet and
weight was subsequently regained. Another patient
(Case 1) developed painless haematuria while on
the synthetic diet, which was detected on routine
urinalysis and remained unexplained despite exhaustsive
diagnostic studies. There was no evidence of congenital
malformation, infection, or bleeding tendency. The diet was never discontinued, and
without treatment the haematuria disappeared after
about one month and has not recurred. There
were no other signs of illness.

Development of secondary sex characteristics
was observed in Case 2 several months before
initiating the synthetic diet (at 14 years); Case 4
demonstrated these developmental changes 2 years
later (at 16 years); Case 1 developed little pubic and
axillary hair until 16-5 years of age; and Case 3
showed no secondary sexual development. Case 5’s
menarche was in her thirteenth year, just before
the start of this study.

Clinical chemistries. The haemoglobin, haematocrit, total protein, and albumin determi-
Effects of Synthetic, Low Phenylalanine Diet on Adolescent Phenylketonuric Patients

Protein constituents of blood, which have relatively short half-lives, provide sensitive indices of change in the body's overall capacity to synthesize protein. Neither these metabolic indicators nor the blood urea nitrogen and cholesterol concentrations showed adverse effects from the synthetic diet, whether balanced or imbalanced with respect to phenylalanine.

Changes in weight and height. Throughout the course of this study we have used stable or increasing weight and height values as evidence of positive nitrogen balance. Fig. 1 indicates the changes in weight and height for each of the 5 phenylketonuric subjects over a 5½-year period, 2 years before and 3½ years after the synthetic diets were imposed. The last point in each curve represents the final measurements after 6 months on the low phenylalanine diet. It will be noted that, in general, weight was well maintained.

Case 5 underwent her pubertal growth spurt before the study and was the only one of the five cases to have grown less than 18–22·5 cm during 3½ years on the synthetic regimens. Furthermore, of the 4 male cases maintained for the final 6 months on the low phenylalanine diet, only Case 4 failed to continue to gain at least 2·5 cm in stature.

Fig. 2 compares the yearly height increments of each child with a normal curve representing the expected acquisition of height-for-age over the same period, beginning in 1965–66 and 1966–67 when the patients were on primarily natural foodstuffs. The height standards for normal school-age children were derived from the Manual for Nutrition Surveys (Interdepartmental Committee on Nutrition for National Defense, 1963). In comparison with these standard height velocities, the rates of growth on synthetic regimens were remarkably satisfactory.

![Fig. 1. Growth on natural and synthetic diets.](http://adc.bmj.com)
It should be added that only 2 (Cases 2 and 5) of the 5 phenylketonuric patients, either before or during the period on synthetic diet, fell within 1 SD of the statural norms, despite satisfactory incremental gains during the latter years. Case 1 had had severe growth retardation from birth, and fell more than 5 SD below the norms. This is compatible with the finding of Mosier that (among 2000 retardates institutionalized in a comparable California state hospital) severe mental defect, without regard to cause, correlated with growth impairment (Mosier, Grossman, and Dingman, 1965). Other studies find, more specifically, that 35 to 50% of retardates 'without obvious organic damage' fall more than 2 SD below the norm for height (Rundle and Sylvester, 1962; Bailit and Whelan, 1967).

In this context, therefore, the relatively normal growth increments on chemical diets (noted in Fig. 2) are the more convincing.

**Effect of imbalanced diet**

*Changes in dietary intake and weight.* Table II shows the average weight for each of the 6 months before the low phenylalanine diet and for each of the 6 months after its initiation. It will be noted that the weights of each of the five patients remained constant or increased slightly—in addition to the aforementioned normal statural gain. There was no detectable change in intake after the low phenylalanine diet was started. In short, these data provide no evidence that the imbalanced character of the diet altered its acceptability or nutritional efficiency.

*Phenylalanine concentrations in plasma.* Fig. 3 indicates the change in blood phenylalanine levels on the low phenylalanine synthetic diet. It will be observed that the fasting blood levels of phenylalanine correlate well with the phenylalanine intake before restriction. After the 80% reduction in dietary phenylalanine, one patient (Case 2),

---

**Fig. 2.—Incremental growth on synthetic diet (normal phenylalanine).** Baseline data represent growth increments attained while on natural food between 1965–66 and 1966–67. Vertical line represents first year on the synthetic diet (1967–68). Normal data are presented at comparable intervals (mean height velocity ± 1 SD).
Effects of Synthetic, Low Phenylalanine Diet on Adolescent Phenylketonuric Patients

TABLE II
Nutritional Response to Low Phenylalanine Diet. Average Weekly Weights 6 Months Before and After Administration of Low Phenylalanine Diet

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Average Daily caloric Intake*</th>
<th>Months</th>
<th>Kilograms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2400</td>
<td>35.0</td>
<td>35.0</td>
</tr>
<tr>
<td>2</td>
<td>2800</td>
<td>52.8</td>
<td>52.8</td>
</tr>
<tr>
<td>3</td>
<td>2400</td>
<td>30.9</td>
<td>30.9</td>
</tr>
<tr>
<td>4</td>
<td>3000</td>
<td>45.0</td>
<td>45.0</td>
</tr>
</tbody>
</table>

*Average intake did not deviate more than 0.1% during any month before or during low phenylalanine regimen.

whose new phenylalanine intake of 10·6 mg/kg per day was well below that of the other patients, reached near normal blood levels in one week. Another (Case 1) who received 14 mg phenylalanine/kg per day, did not reach a blood phenylalanine concentration of 4 mg/100 ml for 17 days. Cases 1 and 2 were maintained between 3·5 mg/100 ml with daily supplements of 389 mg and 83 mg phenylalanine which provided 20·1 mg and 17·8 mg/kg per day, respectively.

On lower phenylalanine intakes (14 and 15 mg phenylalanine/kg per day, respectively) Cases 3 and 4 were unable to establish blood levels below 10 mg/100 ml. After declining to 12 mg/100 ml in 14 days, the phenylalanine concentration in Case 3 dropped very gradually to 10 mg/100 ml, while in the blood of Case 4 the level rose slightly from a low of 12 mg/100 ml and equilibrated at 16 mg/100 ml. By further reducing the phenylalanine intake of Case 4 from 625 mg to 312 mg the blood phenylalanine was brought down to 4 mg/100 ml in 2 weeks. Case 3 reached this therapeutic level when his intake was reduced from 500 mg to 396 mg. Thus, the phenylalanine requirements for Cases 3 and 4 were only 12·8 mg and 6·9 mg/kg per day, respectively.

A major contributor to the apprehension surrounding the administration of phenylalanine-
restricted diets appears to be the misconceived notion that phenylketonuric children need as much phenylalanine as normal youngsters. In this study, where phenylalanine intake could be precisely monitored, it may be seen that the 6·9–20·1 mg/kg per day requirement falls well below the 27–90 mg/kg per day estimate for normal infants and children.

A predictable relation was found between growth and phenylalanine intake (Table III).

### Table III

**Phenylalanine Intake and Growth**

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Terminal Age (yr)</th>
<th>Weight (kg)</th>
<th>Phe Intake (mg/kg per day)</th>
<th>Terminal Height Velocity (cm/yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>17·5</td>
<td>35</td>
<td>17·8</td>
<td>4·0</td>
</tr>
<tr>
<td>2</td>
<td>17·5</td>
<td>53</td>
<td>20·1</td>
<td>5·0</td>
</tr>
<tr>
<td>3</td>
<td>12·0</td>
<td>31</td>
<td>12·8</td>
<td>3·8</td>
</tr>
<tr>
<td>4</td>
<td>17·5</td>
<td>45</td>
<td>6·9</td>
<td>2·2</td>
</tr>
</tbody>
</table>

Thus, Case 2 was growing at the rate of 5 cm per year, and was able to maintain a blood phenylalanine level of 3·5 mg/100 ml with an intake of 20·1 mg/kg per day, while Case 4 grew only 2·2 cm and did not grow at all in the final 6 months, requiring only 6·9 mg/kg per day to maintain the same blood phenylalanine level.

**Change in neurological status.** Anecdotal nursing records give strong evidence of behaviour improvement in Cases 1 and 4. Case 4 had a particularly dramatic change in mood and temperament. As his blood phenylalanine concentration declined to about 12 mg/100 ml, his personality dramatically changed: he was transformed from a whining, irritable child to one who was smiling and responsive. Case 1 also showed a marked improvement in mood with a reduction in his frequent episodes of crying and irritability. This was noted after about 10 days of the low phenylalanine regimen, at which time his blood level was also 10–12 mg/100 ml. At about the same point Case 3 also had some improvement in temperament and in ability to sustain attention while at play. However, Case 2 showed no perceptible change in behaviour until the phenylalanine concentration fell below 5 mg/100 ml.

**Electrophysiological change.** The 3 patients with early behavioural improvement showed objective evidence of EEG improvement also, consisting primarily of readily demonstrable decreases in paroxysmal slow wave activity. This was true on both the 3- and 6-month post-treatment records.

Further evidence of electrophysiological improvement in the summated cortical responses evoked by patterned flash has been observed after plasma phenylalanine levels returned to normal. Preliminary data have been previously noted (Marcus, 1970) and will subsequently be reported in detail. The most consistent therapeutic response was significant shortening of the abnormally prolonged latency times for the visually evoked responses (VER). The decrease in conduction time was most obvious in Cases 3 and 4: they each had a steep drop in latency when blood phenylalanine concentrations fell below 12 mg/100 ml, which was also accompanied by an abrupt increase in blood serotonin and improved behaviour. Case 2, on the other hand, showed a delay in the appearance of electrophysiological and behavioural changes.

Of interest in regard to the neurological improvement are the associated changes in whole blood serotonin, which is thought to be a modulator of nervous system activity. We have noted that serotonin levels usually rise steeply as plasma phenylalanine concentrations approach 12 mg/100 ml (unpublished data). Cases 3 and 4 displayed the most rapid and the highest rises among the 4 treated patients, from 150 to 320 ng per ml. Case 2's serotonin value (125 ng/ml) did not change significantly until the blood phenylalanine dropped below 5 mg/100 ml, at which time the serotonin concentration rose to 270 ng/ml and the VER latency decreased.

These data provide strong presumptive evidence that it is possible to maintain good nutrition and to improve central nervous system function in certain previously untreated, profoundly retarded phenylketonurics, when phenylalanine concentrations are reduced below 12 mg/100 ml using a synthetic dietary preparation. With the help of objective tests of CNS function (such as the VER), it may be practical to identify those patients of any age who will respond to phenylalanine restriction. In such cases, it would be helpful to determine the maximum phenylalanine level that will still permit the observed neurological improvement in order to permit effective dietary planning.

The author wishes to express particular appreciation to Elizabeth Grantham, R.N., and her dedicated staff for their keen interest and careful clinical surveillance throughout the course of these studies and to the Vivonex Corporation for their provision of special dietary formulations.

These investigations supported by United States Public Health Service Research Grant No. 01823 from
Effects of Synthetic, Low Phenylalanine Diet on Adolescent Phenylketonuric Patients

National Institute of Child Health and Human Development.

REFERENCES


Correspondence to Dr. C. M. McKean, Sonoma State Hospital, Eldridge, California 95431, U.S.A.
Effects of totally synthetic, low phenylalanine diet on adolescent phenylketonuric patients

Charles M. McKean

Arch Dis Child 1971 46: 608-615
doi: 10.1136/adc.46.249.608

Updated information and services can be found at:
http://adc.bmj.com/content/46/249/608

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/